China’s National Medical Products Administration (NMPA) Medical Device Technical Review Center released 39 updated medical device registration guidelines effective December 1, 2025; one of the most comprehensive refinements to NMPA registration requirements in recent years. For manufacturers pursuing or maintaining access to the Chinese market, these guidelines are now fully in effect and represent active compliance obligations, not upcoming changes to prepare for.
The December 2025 guidelines did not arrive in isolation. They are part of a coordinated wave of NMPA regulatory modernization that includes: a revised Regulation on the Supervision and Administration of Medical Devices issued January 7, 2025, which offers incentives for overseas manufacturers including priority approval for high-end and urgently needed devices and alignment with international standards; a comprehensive revised Medical Device GMP (Good Manufacturing Practice) published November 4, 2025, taking effect November 1, 2026; and new Clinical Trial Inspection Points that took effect May 1, 2025, targeting data integrity and replacing earlier versions from 2016 and 2018.
Manufacturers that have not yet assessed the impact of the December 2025 guidelines on their active and planned submissions should treat this as an immediate priority.
Scope of the Updated Guidelines
The 39 guidelines cover diagnostic and monitoring devices, therapeutic devices, surgical and procedural instruments, medical equipment and support systems, catheters and vascular devices, and IVD reagents and analytical tools.
IVD manufacturers should note an additional, related development: in May 2024, the CMDE released a new IVD Classification Catalog that came into effect on January 1, 2025, replacing the existing catalog and assigning a structured coding format to in vitro diagnostic reagents. The classification includes both a primary code (labeled 6840-XX) and a secondary sub-category code, selected based on the product’s intended use and specific diagnostic function.
Manufacturers of IVD devices should verify that their product classification aligns with both the new IVD Classification Catalog and the applicable December 2025 guidelines; as misalignment between these two frameworks is a source of submission delays.
Key Regulatory Themes and Changes
Although the 39 guidelines address different device types, several consistent regulatory themes emerge across the updates.
Greater Standardization of Technical Documentation
One of the most significant shifts is the continued push toward standardized medical device dossier requirements China authorities expect. The updated guidelines clarify how technical documentation should be structured, including expectations for product descriptions, intended use statements, risk management files, and safety and performance summaries.
For manufacturers, this reduces ambiguity but also limits flexibility. Submissions that deviate from prescribed structures or lack sufficient detail are more likely to trigger questions or review delays.
The December 2025 guidelines continue NMPA’s push toward standardized dossier structures, including product descriptions, intended use statements, risk management files, and safety and performance summaries. Submissions deviating from prescribed structures or lacking sufficient detail are more likely to trigger questions or review delays.
This documentation standardization is reinforced by the revised 2025 GMP: the revised GMP now specifically addresses the different roles of medical device registrants (for Class II and III devices), filers (for Class I devices), and entrusted manufacturing companies (contract manufacturers), and incorporates the concept of a “dual release” system consisting of production release by the actual manufacturer and market release by the registrant/filer. Manufacturers should ensure their technical documentation accurately reflects these distinctions and that dossier content is consistent with their GMP-level manufacturing documentation.
Stronger Emphasis on Safety and Performance Evidence
The updated NMPA submission requirements 2025 place renewed focus on demonstrating device safety and performance through robust, well-documented evidence. Non-clinical testing data, performance evaluations, and risk mitigation strategies are expected to be comprehensive and clearly justified.
Manufacturers should anticipate closer scrutiny of how testing methodologies align with applicable standards and how performance claims are supported within the dossier.
The updated NMPA guidelines place renewed focus on demonstrating device safety and performance through robust, well-documented evidence. Non-clinical testing data, performance evaluations, and risk mitigation strategies are expected to be comprehensive and clearly justified, with closer scrutiny of how testing methodologies align with applicable standards.
Despite global regulatory reforms, many overseas medical device companies continue to face significant barriers when selling into China — including pricing pressures from Volume-Based Procurement (VBP) programs and government policies placing stricter limits on how many imported devices hospitals can procure. In this environment, a well-evidenced, high-quality dossier is not just a registration requirement; it is a commercial differentiator that influences both regulatory timelines and downstream market access.
Additionally, fifteen newly established or revised industry standards were published October 30, 2025, covering type testing, pre-clinical and clinical studies, and regulatory submissions, with implementation on November 1, 2026. Manufacturers should review these standards alongside the December 2025 guidelines to ensure testing methodologies remain aligned with both current and upcoming requirements.
Clarified Clinical Evaluation Expectations
While clinical evidence requirements vary depending on device risk classification and technology, the revised guidelines provide clearer direction on when clinical data are required and what constitutes acceptable evidence. In some cases, the guidance outlines scenarios where clinical evaluation reports, literature reviews, or local clinical data may be necessary to support registration.
This clarity helps manufacturers plan clinical strategies earlier in the development and registration lifecycle.
The revised guidelines provide clearer direction on when clinical data are required and what constitutes acceptable evidence: including scenarios where clinical evaluation reports, literature reviews, or local clinical data may be necessary to support registration.
A parallel development significantly tightens the clinical trial compliance environment: new Clinical Trial Inspection Points took effect May 1, 2025, replacing versions from 2016 and 2018. This rule applies to product registration applications under review and to approved products for applications under review, inspection results directly affect registration approval outcomes. For approved products, issues found during inspection may trigger a safety assessment, risk control measures, or even revocation of the registration certificate.
The NMPA has published cases of falsified trial data and revoked product registration certificates, demonstrating that clinical trial data integrity enforcement is active, not nominal. Manufacturers should ensure their clinical trial data management systems comply with ALCOA+ data integrity principles, and conduct self-inspections against the 72 medical device inspection points and 54 IVD reagent inspection points in the new rule before submission.
Efforts to Streamline Review Timelines
By standardizing documentation and clarifying expectations, the NMPA aims to improve review efficiency and reduce avoidable back-and-forth during technical review. For compliant submissions, this may translate into more predictable review timelines within the China medical device approval process.
By standardizing documentation and clarifying expectations, NMPA aims to improve review efficiency and reduce avoidable back-and-forth during technical review. For compliant submissions, this may translate into more predictable review timelines.
The January 2025 revised Supervision and Administration Regulation also introduces formal incentives for priority approval for high-end and urgently needed devices, and priority testing for innovative medical devices, a meaningful addition for manufacturers of novel or breakthrough technologies. Manufacturers with innovative devices should assess whether they qualify for these expedited pathways, as they can significantly compress time-to-approval relative to standard review.
Refined Product Classification Guidance
Several guidelines also clarify classification considerations, helping applicants determine the appropriate regulatory pathway. Correct classification is critical, as misclassification can lead to significant delays, additional data requests, or even rejected applications.
Several guidelines clarify classification considerations, helping applicants determine the appropriate regulatory pathway. Correct classification is critical; misclassification can lead to significant delays, additional data requests, or rejected applications.
A potentially transformative classification-adjacent development is also underway: a draft Medical Device Administrative Law (MDAL) released in September 2024 proposes removing the long-standing requirement that imported medical devices must first secure market approval in their country of manufacture before being submitted for China approval. This shift would allow simultaneous regulatory filings in both China and the device’s country of origin; potentially eliminating one of the most significant structural barriers for innovative manufacturers pursuing early Chinese market access. The MDAL remains in draft form as of May 2026, but manufacturers should monitor its progress given its potential to fundamentally change entry strategy planning.
Implications for Manufacturers
The December 2025 guidelines have practical implications at every product lifecycle stage. Higher dossier quality expectations, alignment across testing and claims, updated clinical strategies, and reassessment of active registrations are all required. For organizations managing multiple products, the cumulative impact across portfolios can be significant.
Two additional compliance deadlines now require attention alongside the December 2025 guidelines:
The revised Medical Device GMP takes effect November 1, 2026, giving manufacturers a grace period to review and update internal systems. The 2025 GMP’s most significant structural changes include: a new chapter on Contract Manufacturing and Outsourced Processing; expanded supplier management requirements; strengthened linkage between manufacturing controls and post-market obligations; and integration of risk-based quality management and digital traceability concepts aligned with ISO 13485, EU MDR, and FDA QMSR.
Fifteen revised industry standards published October 30, 2025 will be implemented November 1, 2026, a second November 2026 compliance milestone manufacturers must plan for in parallel with GMP readiness.
For foreign manufacturers specifically: government policies are placing stricter limits on how many imported devices hospitals can procure, and the “Made in China 2025” initiative encourages foreign firms to set up local manufacturing to remain competitive. Foreign manufacturers should factor these commercial dynamics into their China market access strategy alongside registration compliance planning.
Recommended Actions
The December 2025 guidelines are now fully in force. Manufacturers that have not yet assessed their compliance posture should treat the following as immediate priorities:
Conduct a guideline-specific gap assessment for each device against the December 2025 guidelines: identify documentation, testing, or clinical evidence gaps and begin remediation. Update technical files, testing reports, and clinical documentation to align with revised expectations.
Conduct self-inspections against the 72 medical device clinical trial inspection points and 54 IVD inspection points to verify data integrity compliance before active submissions are reviewed. Verify IVD product classification against both the new IVD Classification Catalog (effective January 2025) and applicable December 2025 guidelines.
Begin GMP compliance gap assessment against the revised 2025 GMP, effective November 1, 2026; this gives manufacturers approximately five months from publication of this post to prepare. Review applicability of the January 2025 priority approval pathway for innovative or urgently needed devices. Engage regulatory consultants with China-specific experience to interpret category-level nuances and identify risk proactively.
How RegDesk Can Help
Tracking 39 updated registration guidelines alongside a revised GMP framework, new industry standards, updated clinical trial inspection criteria, and a new IVD classification catalog, all on different implementation timelines, requires a centralized regulatory intelligence approach. RegDesk’s AI-powered RIMS monitors NMPA regulatory changes in real time, helping manufacturers identify how updates across guidelines, GMP requirements, and industry standards affect their specific device portfolios.
From automated gap analysis and dossier development to clinical documentation management and submission tracking, RegDesk gives manufacturers the visibility, efficiency, and confidence needed to navigate China’s evolving compliance landscape.
Conclusion
China’s NMPA has entered one of its most active periods of regulatory modernization in a decade. The 39 updated registration guidelines, now fully in effect, are one part of a coordinated reform effort that includes a revised foundational regulation, a new GMP framework effective November 2026, updated industry standards, and strengthened clinical trial inspection. For manufacturers, the compliance picture in China in 2026 is more demanding and more detailed than at any previous point but also more predictable, with clearer documentation expectations and more transparent review criteria.
Organizations that proactively address the full scope of these developments, not just the December 2025 guidelines in isolation — will be best positioned to maintain compliance, avoid delays, and succeed in China’s rapidly evolving and commercially significant medical device market.
FAQ:
Are the 39 NMPA updated guidelines now in effect, and do they apply to my existing registrations?Yes, the 39 updated medical device registration guidelines from China’s NMPA Medical Device Technical Review Center took effect December 1, 2025. They apply to new submissions filed after that date. For active registrations and submissions already under review, manufacturers should conduct a gap assessment to determine whether existing technical documentation, testing, or clinical evidence meets the updated expectations. Inspection findings can affect both applications under review and approved products; making retroactive compliance assessment essential, not optional.
What is the most significant parallel regulatory development I need to track alongside the December 2025 guidelines? The revised Medical Device GMP, published November 4, 2025 and effective November 1, 2026, is the most significant parallel development. It is the first full revision of China’s device GMP since 2014 and introduces a new chapter on Contract Manufacturing and Outsourced Processing, a dual release system, expanded supplier management requirements, and integration of risk-based quality management aligned with ISO 13485, EU MDR, and FDA QMSR. Manufacturers have until November 2026 to prepare which, combined with December 2025 guideline compliance, creates a significant concurrent workload.
How do the new Clinical Trial Inspection Points affect my registration strategy? The new Clinical Trial Inspection Points, effective May 1, 2025, apply to both applications under review and approved products. For applications under review, inspection results directly affect registration approval outcomes. For approved products, issues found during inspection may trigger a safety assessment, risk control measures, or revocation of the registration certificate. Manufacturers should conduct self-inspections against the 72 medical device inspection points (or 54 IVD inspection points) and verify data integrity compliance with ALCOA+ principles before submitting clinical data as part of any registration.
I manufacture IVDs – what specific NMPA updates apply to me beyond the 39 guidelines? IVD manufacturers face two additional updates: the new IVD Classification Catalog released by CMDE, effective January 1, 2025, assigns a structured coding format (primary code 6840-XX with secondary sub-category codes) based on intended use and diagnostic function. IVD submissions must align with this new catalog in addition to the December 2025 guidelines. Fifteen revised industry standards, including those covering IVD submissions, were published October 30, 2025 and implement November 1, 2026, a third deadline IVD manufacturers must plan for.
Should foreign manufacturers consider local manufacturing in China given these regulatory changes? Government policies are placing stricter limits on how many imported devices hospitals can procure, and the “Made in China 2025” initiative encourages foreign firms to set up local manufacturing to remain competitive. Volume-Based Procurement (VBP) programs have also slashed reimbursement for many foreign-made devices. At the same time, the January 2025 Supervision and Administration Regulation introduces incentives for overseas manufacturers including priority approval for high-end devices and alignment with international standards, and the draft MDAL proposes removing the country-of-manufacture pre-approval requirement. Foreign manufacturers should evaluate the local manufacturing question as a commercial strategy decision in parallel with registration compliance; both dynamics are actively evolving.
